{"meta":{"query_hash":"6ae379aee0dd","filters":{"venue":"Prospects in Pharmaceutical Sciences"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6ae379aee0dd","api":"https://metacan.xera.ac/api/v1/cohort?venue=Prospects+in+Pharmaceutical+Sciences"},"results":[{"id":"W4403384077","doi":"10.56782/pps.262","title":"Mirikizumab – a new option in treatment of inflammatory bowel diseases","year":2024,"lang":"en","type":"article","venue":"Prospects in Pharmaceutical Sciences","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Inflammatory Bowel Diseases; Medicine; Inflammatory bowel disease; Intensive care medicine; Internal medicine; Disease","score_opus":0.023110620984883062,"score_gpt":0.34007271074247075,"score_spread":0.31696208975758766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403384077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076603953,0.99514633,0.000335288,0.00085082516,0.00036692098,0.000008774963,0.000038870377,0.0000142245735,0.0024726833],"genre_scores_gemma":[0.009333203,0.9865507,0.0009121582,0.0008249351,0.00066757353,0.000018929903,0.00008795641,0.000004676895,0.0015998497],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999853,0.000041659878,0.000025024083,0.00002212147,0.00004634854,0.000011730397],"domain_scores_gemma":[0.99986553,0.00006015402,0.00002876686,0.0000044656886,0.000028560147,0.000012481682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039528756,0.00026188703,0.00058009196,0.0012823322,0.00013246281,0.0006217385,0.00024510926,0.00045737388,0.0043906453],"category_scores_gemma":[0.0003439198,0.0001035771,0.00038881283,0.00094687316,0.00023081944,0.00089861767,0.0003065574,0.00090429076,0.0014684141],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003871138,0.00009020297,0.00035513993,0.015582182,0.00016611177,0.0006204728,0.00009859505,0.00023525947,0.012463678,0.0061964914,0.021320267,0.9424845],"study_design_scores_gemma":[0.000096124866,0.0004554411,0.0021282616,0.0038709096,0.00021824458,0.0024075962,0.00008056857,0.00015258086,0.0024769474,0.0033334785,0.98475593,0.000023858423],"about_ca_topic_score_codex":0.00019108845,"about_ca_topic_score_gemma":0.00052386406,"teacher_disagreement_score":0.0043906453,"about_ca_system_score_codex":0.00022124355,"about_ca_system_score_gemma":0.00034234617,"threshold_uncertainty_score":0.014688194},"labels":[],"label_agreement":null}]}